Quick answer: AKASA and Waystar solve different layers. AKASA is mid-cycle AI for coding, CDI, and denial operations in health systems. Waystar is a clearinghouse and payments platform with AltitudeAI for denial prevention on 837/835 traffic. Neither replaces the other. Keep Waystar for submission if you already route there. Choose AKASA only if the program is documentation and mid-cycle ops, not claims routing.
Inclusion criteria: Head-to-head on deployment model, EHR fit, payer coverage, and whether you must replace a clearinghouse or BPO.
Honest limitations: Substrate does not replace a clearinghouse, EHR, coder, or patient-billing platform. It automates post-submission AR. Claim status includes denial root-cause analysis (eligibility, records, medical necessity, wrong route), not just a 277 code or an 835 variance. Clinical edge cases still go to staff. Coding, CDI, and patient-facing billing are out of scope.
At a glance
Where AKASA wins
- Coding and CDI quality programs at multi-hospital scale
- Denial operations tied to clinical documentation, not just 835 variances
- Buyers who already have a clearinghouse and want mid-cycle AI
Where Waystar wins
- Claims routing, remits, and KLAS-cited clearinghouse scale
- AltitudeAI denial prevention on submitted claims
- One vendor for payments platform plus analytics if you will adopt Waystar
Also consider Substrate
Also consider Substrate when the gap is post-submission follow-up on the current PM: live in days, EDI and portal coverage across 3,500+ payers, PM writeback with a video audit trail, and denial root-cause analysis as part of claim status (eligibility, records, medical necessity, or wrong route) rather than a 277 code or an 835 variance alone. Substrate does not replace a clearinghouse, EHR, coder, or patient-billing platform. Keep Waystar for 837/835. AKASA can stay on mid-cycle work. Add an overlay when billers still live in portals after the 277 and need the unpaid reason, not another code.
Research sources
AKASA product materials, Waystar KLAS clearinghouse citations, and 2026 buyer guides on 276/277 limits. Verify modules and payer enrollment in your RFP.